Samsung Biologics Expands CDMO Reach with 60,000L GSK Facility Acquisition and Strategic PolyPeptide Group Buyout

August 23, 2026

Samsung Biologics South Korea

Overview

Samsung Biologics significantly bolstered its CDMO capabilities by acquiring a 60,000-liter GSK facility in Maryland, boosting total capacity to 845,000 liters, and agreeing to acquire PolyPeptide Group for CHF 1.46 billion to enter the peptide therapeutics market. These strategic moves, alongside investments in an open innovation hub and BioCampus III for next-gen modalities, underscore Samsung’s aggressive global expansion and modality diversification. The company has now secured approximately $13 billion in long-term manufacturing contracts, driving global biopharmaceutical manufacturing competition.

In Depth

Key Findings

Samsung Biologics has significantly expanded its global footprint and service offerings by acquiring a former GSK manufacturing facility in Maryland, USA, increasing its total production capacity to 845,000 liters. Concurrently, the company announced an agreement to acquire PolyPeptide Group for CHF 1.46 billion (approximately $1.8 billion USD), marking a strategic entry into the peptide therapeutics market. These aggressive moves are set to accelerate Samsung’s modality diversification and global operational reach.

Technical and Clinical Details

The newly acquired Maryland facility adds 60,000 liters of cGMP (Current Good Manufacturing Practice) capacity, substantially augmenting Samsung Biologics’ existing bioreactor fleet. This expansion is critical for addressing the escalating demand for monoclonal antibodies and other biologics. The acquisition of PolyPeptide Group integrates peptide synthesis capabilities into Samsung’s portfolio, which already encompasses cell line development, process development, and cGMP manufacturing for large molecule biologics. This broadens the company’s ability to serve diverse client needs, from complex small molecules to large biopharmaceuticals.

Background and Industry Context

2026 stands out as a year of aggressive investment by CDMOs in manufacturing capacity and modality diversification, driven by the rapid growth of the biopharmaceutical market. Samsung Biologics has been at the forefront of this trend, having already secured long-term manufacturing contracts totaling approximately $13 billion. Other industry leaders like Lonza are investing CHF 500 million in a Swiss fill-finish facility, and Resilience is committing $750 million to US production through an expanded partnership with Eli Lilly. The Asia-Pacific region, in particular, is emerging as the fastest-growing CDMO market, supported by government incentives and extensive capacity expansion; Samsung Biologics’ actions further solidify its role as a regional hub. The company is also establishing an open innovation hub in South Korea and securing land for BioCampus III to support next-generation modalities, demonstrating a robust long-term growth strategy.

Future Outlook

Samsung Biologics’ recent acquisitions and substantial investments position it as a global leader offering end-to-end services across all stages of biopharmaceutical development and manufacturing. Its entry into the peptide therapeutics market is a strategic step towards expanding into advanced modalities like cell and gene therapies, potentially forming a new pillar of its future business. As global supply chains demand greater diversification and resilience, Samsung’s geographical and modality expansion is expected to accelerate client product development and ultimately contribute to delivering innovative therapies to more patients worldwide.

Source: https://samsungbiologics.com/media/company-news/cdmos-expand-and-build-for-future-growth

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.